Avadomide

Drug Profile

Avadomide

Alternative Names: CC 122

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Hepatocellular carcinoma
  • Phase I Diffuse large B cell lymphoma; Glioblastoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 05 Jul 2017 Avadomide licensed to BeiGene in China
  • 22 Jun 2017 Efficacy and adverse event data from a phase Ib trial in Non-Hodgkin's Lymphoma presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 17 Apr 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top